Top

Published in:

01-05-2007 | Symposium Paper

Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy

Authors: Andreas Hombach, Hinrich Abken

Published in: Cancer Immunology, Immunotherapy | Issue 5/2007

Abstract

Redirecting T cell effector functions towards pre-defined target cells represents an attractive concept in the adoptive immunotherapy of malignant diseases. Our understanding of the mechanisms of T cell activation and costimulation as well as the design of recombinant T cell receptors have made major progress in the last years. Translating recent concepts of T cell stimulation into recombinant protein design provides the basis to engineer T cells with both pre-defined specificity and costimulatory capacity in order to enhance anti-tumor immunity and to break tolerance. Dual signaling immunoreceptors providing the CD3ζ signal simultaneously with an appropriate costimulatory signal moreover allows to modulate the quality of the anti-tumor T cell response in a predicted fashion.

Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365CrossRefPubMed

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677–685CrossRefPubMed

Schumacher TN (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2:512–519CrossRefPubMed

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Opalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A., de Vries CR, Rogers-Freezer LJ, Maroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129CrossRefPubMed

Gross G, Gorochov G, Waks T, Eshhar Z (1989) Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21:127–130PubMed

Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720–724CrossRefPubMed

Abken H, Hombach A, Heuser C (2003) Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 9:1992–2001CrossRefPubMed

Hombach A, Heuser C, Abken H (2002) The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther 2:211–226CrossRefPubMed

Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Kruis W, Pohl C, Abken H (1997) T cell targeting of TAG72 + tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 113:1163–1170CrossRefPubMed

10.

Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Honemann D, Prince HM, Darcy PK, Kershaw MH (2005) Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 102:19051–19056CrossRefPubMed

11.

Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B (1996) Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 2:1001–1008PubMed

12.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJDarcy PK (2002) Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 169:5780–5786PubMed

13.

Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IG, Abken H (2006) A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3ζ-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55:1156–1164CrossRefPubMed

14.

Hombach A, Muche JM, Gerken M, Gellrich S, Heuser C, Pohl C, Sterry W, Abken H (2001) T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells. Gene Ther 8:891–895CrossRefPubMed

15.

Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C, Abken H (2001) CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J Immunol 167:1090–1096PubMed

16.

Hombach A, Köhler H, Rappl G, Abken H (2006) Human CD4+ T cells lyse tumor cells via granzyme/perforin upon circumvention of MHC restriction by grafting with a recombinant, antibody-derived immunoreceptor. J Immunol 177:5668-675

17.

Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105:3087–3093CrossRefPubMed

18.

Brocker T, Riedinger M, Karjalainen K (1996) Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur J Immunol 26:1770–1774CrossRefPubMed

19.

Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H (2001) T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 61:1976–1982PubMed

20.

Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL (1998) Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 77:181–187CrossRefPubMed

21.

Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26:2304–2309CrossRefPubMed

22.

Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791–2797PubMed

23.

Eshhar Z, Waks T, Bendavid A, Schindler DG (2001) Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248:67–76CrossRefPubMed

24.

Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20:70–75CrossRefPubMed

25.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155–3163CrossRefPubMed

26.

Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H (2001) Tumor specific T cell activation by recombinant immunoreceptors: CD3zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol 167:6123–6131PubMed

27.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 11:371–379CrossRefPubMed

28.

Geiger TL, Nguyen P, Leitenberg D, Flavell RA (2001) Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in lymphocytes. Blood 98:2364–2371CrossRefPubMed

29.

Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104–113PubMed

30.

Zhong XS, Matsushita M, Saudemont A, Santos E, Sadelain M (2006) Integrated CD28 and 4-1BB signals strongly potentiate CD8+ T cell mediated eradication of metastatic prostate cancer. Mol Ther 13(Suppl1):S103CrossRef

31.

Weinberg AD (2002) OX40: targeted immunotherapy–implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23:102–109CrossRefPubMed

32.

Huard B, Schneider P, Mauri D, Tschopp J, French LE (2001) T cell costimulation by the TNF ligand BAFF. J Immunol 167:6225–6231PubMed

33.

Mestas J, Hughes CC (2001) Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation. J Immunol 167:4378–4385PubMed

34.

Lamers CH, Sleijfer S., Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20–e22CrossRefPubMed

Title: Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy
Authors: Andreas Hombach
Hinrich Abken
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0249-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2007

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer

Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells

Tumor specific phage particles promote tumor regression in a mouse melanoma model

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles

HLA-A0201 positive pancreatic cell lines: new findings and discrepancies

Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer